全文获取类型
收费全文 | 2236篇 |
免费 | 379篇 |
国内免费 | 61篇 |
专业分类
电工技术 | 8篇 |
综合类 | 31篇 |
化学工业 | 1895篇 |
金属工艺 | 171篇 |
机械仪表 | 14篇 |
建筑科学 | 15篇 |
矿业工程 | 26篇 |
能源动力 | 24篇 |
轻工业 | 258篇 |
水利工程 | 3篇 |
石油天然气 | 55篇 |
无线电 | 13篇 |
一般工业技术 | 50篇 |
冶金工业 | 32篇 |
原子能技术 | 11篇 |
自动化技术 | 70篇 |
出版年
2024年 | 2篇 |
2023年 | 42篇 |
2022年 | 48篇 |
2021年 | 270篇 |
2020年 | 99篇 |
2019年 | 102篇 |
2018年 | 99篇 |
2017年 | 73篇 |
2016年 | 121篇 |
2015年 | 123篇 |
2014年 | 138篇 |
2013年 | 186篇 |
2012年 | 163篇 |
2011年 | 164篇 |
2010年 | 133篇 |
2009年 | 165篇 |
2008年 | 113篇 |
2007年 | 104篇 |
2006年 | 102篇 |
2005年 | 64篇 |
2004年 | 63篇 |
2003年 | 56篇 |
2002年 | 44篇 |
2001年 | 37篇 |
2000年 | 22篇 |
1999年 | 12篇 |
1998年 | 11篇 |
1997年 | 12篇 |
1996年 | 6篇 |
1995年 | 14篇 |
1994年 | 14篇 |
1993年 | 9篇 |
1992年 | 14篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 8篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有2676条查询结果,搜索用时 296 毫秒
101.
Dr. Holger Siebeneicher Dr. Arwed Cleve Dr. Hartmut Rehwinkel Dr. Roland Neuhaus Dr. Iring Heisler Dr. Thomas Müller Dr. Marcus Bauser Dr. Bernd Buchmann 《ChemMedChem》2016,11(20):2261-2271
Despite the long‐known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1‐selective small‐molecule inhibitor. Because other transporters of the GLUT1 family are involved in crucial processes, these transporters should not be addressed by such an inhibitor. A high‐throughput screen against a library of ~3 million compounds was performed to find a small molecule with this challenging potency and selectivity profile. The N‐(1H‐pyrazol‐4‐yl)quinoline‐4‐carboxamides were identified as an excellent starting point for further compound optimization. After extensive structure–activity relationship explorations, single‐digit nanomolar inhibitors with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4 were obtained. The most promising compound, BAY‐876 [N4‐[1‐(4‐cyanobenzyl)‐5‐methyl‐3‐(trifluoromethyl)‐1H‐pyrazol‐4‐yl]‐7‐fluoroquinoline‐2,4‐dicarboxamide], showed good metabolic stability in vitro and high oral bioavailability in vivo. 相似文献
102.
Huiding Xie Kaixiong Qiu Xiaoguang Xie 《International journal of molecular sciences》2014,15(11):20927-20947
Aromatase inhibitors are the most important targets in treatment of estrogen-dependent cancers. In order to search for potent steroidal aromatase inhibitors (SAIs) with lower side effects and overcome cellular resistance, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on a series of SAIs to build 3D QSAR models. The reliable and predictive CoMFA and CoMSIA models were obtained with statistical results (CoMFA: q2 = 0.636, r2ncv = 0.988, r2pred = 0.658; CoMSIA: q2 = 0.843, r2ncv = 0.989, r2pred = 0.601). This 3D QSAR approach provides significant insights that can be used to develop novel and potent SAIs. In addition, Genetic algorithm with linear assignment of hypermolecular alignment of database (GALAHAD) was used to derive 3D pharmacophore models. The selected pharmacophore model contains two acceptor atoms and four hydrophobic centers, which was used as a 3D query for virtual screening against NCI2000 database. Six hit compounds were obtained and their biological activities were further predicted by the CoMFA and CoMSIA models, which are expected to design potent and novel SAIs. 相似文献
103.
DNA methylation is an epigenetic change that results in the addition of a methyl group at the carbon-5 position of cytosine residues. DNA methyltransferase (DNMT) inhibitors can suppress tumour growth and have significant therapeutic value. However, the established inhibitors are limited in their application due to their substantial cytotoxicity. Additionally, the standard drugs for DNMT inhibition are non-selective cytosine analogues with considerable cytotoxic side-effects. In the present study, we have designed a workflow by integrating various ligand-based and structure-based approaches to discover new agents active against DNMT1. We have derived a pharmacophore model with the help of available DNMT1 inhibitors. Utilising this model, we performed the virtual screening of Maybridge chemical library and the identified hits were then subsequently filtered based on the Naïve Bayesian classification model. The molecules that have returned from this classification model were subjected to ensemble based docking. We have selected 10 molecules for the biological assay by inspecting the interactions portrayed by these molecules. Three out of the ten tested compounds have shown DNMT1 inhibitory activity. These compounds were also found to demonstrate potential inhibition of cellular proliferation in human breast cancer MDA-MB-231 cells. In the present study, we have utilized a multi-step virtual screening protocol to identify inhibitors of DNMT1, which offers a starting point to develop more potent DNMT1 inhibitors as anti-cancer agents. 相似文献
104.
105.
The inhibitive effects of the dibutyl phosphate anion in cerium dibutylphosphate [Ce(dbp)3] on AA 2024-T351 immersed in 0·05M NaCl were evaluated by comparison with immersion in cerium chloride (CeCl3) in 0·05M NaCl as well as 0·05M NaCl alone. Scanning electron microscopy and energy dispersive X-ray hyperspectral mapping were used to examine the surfaces after exposure to the different inhibitor solutions. It was found that the dibutylphosphate anion produced additional inhibition for the matrix and the S phase intermetallic particles. The most significant mode of corrosion in the absence of inhibitors was in the form of rings of corrosion product. CeCl3 largely suppressed the formation of the rings of corrosion product, and the Ce(dbp)3 entirely eliminated them (for the time scales investigated here), indicating the additional inhibitive action of the dibutylphosphate anion. 相似文献
106.
107.
Preparation and optimisation of liposome‐in‐alginate beads containing oyster hydrolysate for sustained release 下载免费PDF全文
Cheng‐liang Xie Su‐Seon Lee Se‐young Choung Sang Soo Kang Yeung Joon Choi 《International Journal of Food Science & Technology》2016,51(10):2209-2216
Oyster (Crassostrea gigas) hydrolysate shows antihypertensive effect in our previous study. Oral administration of oyster hydrolysate can loss bioactive peptides due to enzymatic degradation in vivo. To maximise its bioavailability, liposome‐in‐alginate (LA) beads were used to encapsulate the oyster hydrolysates to protect from degradation and obtain sustained release. The preparation conditions of the LA beads were optimised by response surface method using a model peptide of tyrosylalanine (YA). Their characterisation, swelling and release properties were investigated. The optimised conditions for the concentration of calcium chloride, sodium alginate and the amount of ethanol‐dissolved lecithin (EDL) were 0.5 m , 3% and 95.4 mg, respectively. The encapsulation efficiencies of YA and the oyster hydrolysate in the optimised condition were 74.9% and 84.3%, respectively. The release time of the oyster hydrolysate in the simulated gastrointestinal fluid was up to 16 h. The LA beads can be recommended to encapsulate oyster hydrolysate for bioavailability improvement. 相似文献
108.
Yasmine Boudida Mohammed Gagaoua Samira Becila Brigitte Picard Abdelghani Boudjellal Carlos H. Herrera-Mendez 《Critical reviews in food science and nutrition》2016,56(6):957-972
Since years, serine proteases and their inhibitors were an enigma to meat scientists. They were indeed considered to be extracellular and to play no role in postmortem muscle proteolysis. In the 1990's, we observed that protease inhibitors levels in muscles are a better predictor of meat tenderness than their target enzymes. From a practical point of view, we therefore choose to look for serine protease inhibitors rather than their target enzymes, i.e. serine proteases and the purpose of this report was to overview the findings obtained. Fractionation of a muscle crude extract by gel filtration revealed three major trypsin inhibitory fractions designed as F1 (Mr:50–70 kDa), F2 (Mr:40–60 kDa) and F3 (Mr:10–15kD) which were analyzed separately. Besides antithrombin III, an heparin dependent thrombin inhibitor, F1 and F2 comprised a large set of closely related trypsin inhibitors encoded by at least 8 genes bovSERPINA3-1 to A3-8 and able to inhibit also strongly initiator and effector caspases. They all belong to the serpin superfamily, known to form covalent complexes with their target enzymes, were located within muscle cells and found in all tissues and fluids examined irrespective of the animal species. Potential biological functions in living and postmortem muscle were proposed for all of them. In contrast to F1 and F2 which have been more extensively investigated only preliminary findings were provided for F3. Taken together, these results tend to ascertain the onset of apoptosis in postmortem muscle. However, the exact mechanisms driving the cell towards apoptosis and how apoptosis, an energy dependent process, can be completed postmortem remain still unclear. 相似文献
109.
Kehua Wu Larry House Wanqing Liu William C.S. Cho 《International journal of molecular sciences》2012,13(9):11471-11496
Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical characterizations, prognosis, response and tolerance to treatment. Personalized medicine refers to the use of markers to predict which patient will most likely benefit from a treatment. In lung cancer, the well-developed epidermal growth factor receptor (EGFR) and the newly emerging EML4-anaplastic lymphoma kinase (ALK) are important therapeutic targets. This review covers the basic mechanism of EGFR and EML4-ALK activation, the predictive biomarkers, the mechanism of resistance, and the current targeted tyrosine kinase inhibitors. The efficacy of EGFR and ALK targeted therapies will be discussed in this review by summarizing the prospective clinical trials, which were performed in biomarker-based selected patients. In addition, the revolutionary sequencing and systems strategies will also be included in this review since these technologies will provide a comprehensive understanding in the molecular characterization of cancer, allow better stratification of patients for the most appropriate targeted therapies, eventually resulting in a more promising personalized treatment. The relatively low incidence of EGFR and ALK in non-Asian patients and the lack of response in mutant patients limit the application of the therapies targeting EGFR or ALK. Nevertheless, it is foreseeable that the sequencing and systems strategies may offer a solution for those patients. 相似文献
110.